SBPL-0600: An Oncolytic Virotherapy with a Potential to Personalize Cancer Therapy
Vishwas Joshi,
Director,
Seagull BioSolutions Pvt Ltd
Oncolytic Virotherapy has emerged as a new paradigm for cancer treatment. T-Vec from Amgen is already approved & other Oncotherapeutic Viruses (OV) may be approved soon. More recently Measles vaccine virus (MV) has emerged as another type of oncotherapeutic virus (oMV) with potential to cure established cancers clinically. Proven safety, ease of manufacture, ease of inserting large amount (~35%) genetic material & ease of re-targeting MV make it an attractive virus for oncovirotherapy. However, anti-OV immunity and high costs may hinder wider use of oMV and other OV. We have produced a rec. MV (SBPL-0600) capable of delivering soluble PD-1 (sPD-1) and human GMCSF into cancer environment using a proprietary 2 plasmid system for reverse genetics of Measles virus; killed Breast, Lung and Prostate cancer cell lines in vitro and also inhibited A549 tumor growth in a nude mice. SBPL-0600 also stimulated normal human PBMCs cells to kill these cancer cells ex vivo, in a Tumor Neutralization assay. Administration of DNA molecules (SBPL-0610) used for producing SBPL-0600, produced similar oncolytic effect in vitro & in vivo. OV-producing DNA formulations may help circumvent the problem of anti-MV immunity and also allow personalization of OV therapy.
|
|
